Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 12/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.33 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.31 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13614934 | 1.00 | P2RY12 (0.34) | P2RY12P2RY2P2RY6DNPH1TRPM2 | |
| SCHEMBL13614516 | 0.93 | P2RY12 (0.35) | P2RY12P2RY2P2RY6DNPH1P2RY4 | |
| SCHEMBL14017341 | 0.93 | P2RY12 (0.35) | P2RY12P2RY2P2RY6DNPH1P2RY4 | |
| SCHEMBL16349151 | 0.89 | P2RY2 (0.31) | P2RY2P2RY6 | |
| SCHEMBL14017300 | 0.80 | P2RY2 (0.42) | P2RY2P2RY6DNPH1TRPM2P2RY4 | |
| SCHEMBL13614498 | 0.80 | P2RY2 (0.42) | P2RY2P2RY6DNPH1TRPM2P2RY4 | |
| SCHEMBL13614550 | 0.74 | P2RY2 (0.41) | P2RY2P2RY6DNPH1P2RY4 | |
| SCHEMBL13614888 | 0.74 | P2RY2 (0.41) | P2RY2P2RY6DNPH1P2RY4 | |
| SCHEMBL16326152 | 0.74 | — | — | |
| SCHEMBL13614497 | 0.72 | B4GALT1 (0.43) | P2RY2P2RY6TRPM2P2RY4B4GALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612047-B2 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | DOUGLASS III JAMES G | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | PNKP, ENTPD5, ENPP1 | P2RY12 65/4885P2RY2 75/4885P2RY6 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.